I. Pardos

Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.

J. Baselga, J. Tabernero, J. Smyth, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

P. Kantoff, M. Michaelson, R. J. Lee, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

P. Kantoff, M. Michaelson, J. Bellmunt, 2012 .